Duration of Heart Failure With Reduced Ejection Fraction Associated With Electrocardiographic Outcomes Before and After Sacubitril/Valsartan
Aim: Changes in QRS duration in patients with heart failure with reduced ejection fraction (HFrEF) after sacubitril/valsartan therapy is not fully understood. This study aimed to assess the association of duration of HFrEF diagnosis with electrocardiographic and echocardiographic outcomes between be...
Saved in:
Main Authors: | Po-Lin Lin MD (Author), Ying-Hsiang Lee MD (Author), Lawrence Yu-Min Liu MD, PhD (Author), Cheng-Ting Tsai MD (Author), Ten-Fang Yang MD (Author), Wei-Ru Chiou MD (Author), Mu-Yang Hsieh MD (Author), Hung-Yu Chang MD (Author), Chun-Che Huang PhD (Author) |
---|---|
Format: | Book |
Published: |
SAGE Publishing,
2022-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Up-Titration of Sacubitril/Valsartan Among Patients With Heart Failure and Preserved Ejection Fraction
by: Koichiro Matsumura MD, et al.
Published: (2023) -
The Efficacy and Safety of Sacubitril/Valsartan in Heart Failure Patients: A Review
by: Rui Zhang MD, PhD, et al.
Published: (2022) -
Predicting Hospital Readmissions in Patients Receiving Novel-Dose Sacubitril/Valsartan Therapy: A Competing-Risk, Causal Mediation Analysis
by: Changchun Hou MD, et al.
Published: (2023) -
Comparison of the Efficacy and Safety of Sacubitril/Valsartan and Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Patients With Reduced Ejection Fraction Combined With Moderate-to-Severe Chronic Kidney Disease
by: Zhaowei Zhang MD, et al.
Published: (2024) -
Dapagliflozin versus sacubitril-valsartan for heart failure with mildly reduced or preserved ejection fraction
by: Ronen Arbel, et al.
Published: (2024)